- Correction
- Open access
- Published:
Correction: NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism
Molecular Medicine volume 31, Article number: 182 (2025)
Correction: Mol Med 31, 3 (2025)
https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s10020-024-01062-9
In this article (Wang et al. 2025) the wrong figure appeared in Fig. 5K and have now been corrected in the original publication. For completeness and transparency, both correct and incorrect versions are displayed below.
The original article has been corrected.
Incorrect Fig. 5
ASNS serves as a downstream molecule of NEK8. A IP-MS analysis revealed a significant correlation between NEK8 and ASNS. B, C ASNS levels were significantly elevated in GC cells compared to GES-1 cells. D Immunohistochemical analysis of a large-sample tissue microarray showed that ASNS was markedly overexpressed in GC tissues. E Kaplan–Meier survival analysis indicated that high ASNS expression is associated with a worse prognosis in patients with GC. F, G Pearson correlation analysis demonstrated a positive relationship between NEK8 expression and ASNS IHC staining. H, I IF and Western blot analyses confirmed that NEK8 significantly regulates ASNS protein expression. J The inhibition of ASNS protein expression by NEK8 knockdown was reversed by treatment with MG132. K NEK8 protein was pulled down using specific antibody and then ASNS protein was detected in the immunoprecipitated protein lysate of NEK8. L Subsequently, ASNS was also pulled down, and NEK8 could also be detected in the immunoprecipitated protein lysate of ASNS. *P < 0.05, **P < 0.01, ***P < 0.001
Correct Fig. 5
ASNS serves as a downstream molecule of NEK8. A IP-MS analysis revealed a significant correlation between NEK8 and ASNS. B, C ASNS levels were significantly elevated in GC cells compared to GES-1 cells. D Immunohistochemical analysis of a large-sample tissue microarray showed that ASNS was markedly overexpressed in GC tissues. E Kaplan–Meier survival analysis indicated that high ASNS expression is associated with a worse prognosis in patients with GC. F, G Pearson correlation analysis demonstrated a positive relationship between NEK8 expression and ASNS IHC staining. H, I IF and Western blot analyses confirmed that NEK8 significantly regulates ASNS protein expression. J The inhibition of ASNS protein expression by NEK8 knockdown was reversed by treatment with MG132. K NEK8 protein was pulled down using specific antibody and then ASNS protein was detected in the immunoprecipitated protein lysate of NEK8. L Subsequently, ASNS was also pulled down, and NEK8 could also be detected in the immunoprecipitated protein lysate of ASNS. *P < 0.05, **P < 0.01, ***P < 0.001
Reference
Wang M, Yu K, Meng F, et al. NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism. Mol Med. 2025;31:3. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s10020-024-01062-9.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wang, M., Yu, K., Meng, F. et al. Correction: NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism. Mol Med 31, 182 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s10020-025-01234-1
Published:
DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s10020-025-01234-1